Ignite Creation Date:
2025-12-24 @ 2:28 PM
Ignite Modification Date:
2026-01-06 @ 9:17 PM
Study NCT ID:
NCT03600259
Status:
UNKNOWN
Last Update Posted:
2022-11-02
First Post:
2018-07-06
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Tianjin Inpatient Acute Myocardial Infarction Registry
Sponsor:
Tianjin Chest Hospital
Organization:
Study Overview
Official Title:
Cohort Study of Acute Myocardial Infarction in Tianjin
Status:
UNKNOWN
Status Verified Date:
2022-11
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TAMI
Brief Summary:
Acute myocardial infarction(AMI) is the most serious manifestation of coronary artery disease. AMI is characterized by high mortality, high disability, and high cost. However, multicenter research on AMI with large sample size in Tianjin or even China is limited. By including AMI in 36 hospitals,this multicenter study will capture the changes in epidemiological trends ,analyze the status of treatment in Tianjin, and explore the best treatment strategies.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: